Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
Ono's antisense therapy is to begin its first pivotal trial.
The Japanese group licenses sapablursen from Ionis for $280m.
